Search for drugs:
Typing the drug name to query
RIVAROXABAN
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- QT/QTc Prolongation
- Cardiac Electrophysiology
- In a thorough QT study in healthy men and women aged 50 years and older, no QTc prolonging effects were observed for XARELTO (15 mg and 45 mg, single-dose).
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
22
24070
Other ADRs
230116
38151471
Odds Ratio = 0.152
Drug Property Information
ATC Code(s):
- B01AF01 - rivaroxaban
- B01AF0 -
- B01AF -
- B01A - ANTITHROMBOTIC AGENTS
- B01 - ANTITHROMBOTIC AGENTS
- B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:rivaroxaban
Active Ingredient UNII:9NDF7JZ4M3
Drugbank ID:DB06228
PubChem Compound:9875401
CTD ID:D000069552
CAS Number:366789-02-8
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 20.0 mg/day B01AF01
Chemical Structure: 
SMILE Code:
ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.